Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

31.84USD
15 Feb 2019
Change (% chg)

$0.32 (+1.02%)
Prev Close
$31.52
Open
$31.91
Day's High
$31.91
Day's Low
$31.59
Volume
1,069,344
Avg. Vol
1,819,135
52-wk High
$44.17
52-wk Low
$26.04

Select another date:

Tue, Feb 12 2019

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

Mylan launches Advair generic at one-third price

Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

Mylan launches Advair generic at one-third price

Feb 12 Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 percent lower than the branded medicine.

FDA approves Mylan's generic of Advair asthma treatment

The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.

FDA approves Mylan's generic of Advair asthma treatment

Jan 30 The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.

South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

UPDATE 1-South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG, Dec 13 Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

Mylan says Sanofi loses Lantus insulin patent claims

U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

UPDATE 2-Mylan says Sanofi loses Lantus insulin patent claims

Dec 13 U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

Mylan says patent office cancels Sanofi's Lantus patents

Dec 13 Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker.

Select another date: